Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 15/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20156313 | 0.89 | HRH1 (0.50) | SUCNR1HRH1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL30930276 | 0.83 | SUCNR1 (0.50) | SUCNR1PDE10AOXGR1 | |
| SCHEMBL6129289 | 0.83 | KCNH2 (0.55) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL276117 | 0.83 | SUCNR1 (0.50) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL19952703 | 0.82 | ALDH1A1 (0.47) | SUCNR1HRH1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL20517681 | 0.81 | SUCNR1 (0.49) | SUCNR1PDE10AOXGR1 | |
| SCHEMBL12895009 | 0.80 | PDE10A (0.49) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL29797374 | 0.80 | SUCNR1 (0.45) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL20153361 | 0.80 | SUCNR1 (0.45) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL3395898 | 0.79 | HSP90AA1 (0.45) | HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| US-8901144-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901144-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| EP-1235828-B1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO INC (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1235828-A4 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO INC (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1235828-A1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | Merck & Co., Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6423845-B1 | CYCLIZATION A 2-AMINO-3-FORMYLPYRIDINE COMPOUND; BONE DISORDERS, OSTEOPOROSIS | MERCK & CO., INC. | 2002-07-23 | — | — | US | disclosed |
| WO-2001038328-A1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | ITGB3, ITGA2, ITGA1 | SUCNR1 825/4885HRH1 1377/4885PDE10A 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.